Optimising Treatment in Myelofibrosis, Considerations for Ruxolitinib Resistance

01 Apr 2024
Optimising Treatment in Myelofibrosis, Considerations for Ruxolitinib Resistance
At the recent MPN Expert Forum virtual symposium, Professor Claire Harrison shared her experience in managing real-world myelofibrosis and further discussed treatment options in the event of ruxolitinib failure.
Sponsored as an educational program by Novartis Corporation (Malaysia) Sdn Bhd

Related MIMS Drugs

Resources

MY-NOV-318

MY-NOV-318

MY-NOV-318

MY-NOV-318